Deltagen, Inc. engages in the provision of drug discovery tools and services to the biopharmaceutical industry. The company is headquartered in San Carlos, California. The company went IPO on 2000-08-03. The firm offers a suite of programs designed to manage the efficiency of drug discovery, including access to biological models, as well as both small-molecule and secreted protein drug targets. In addition, it offers target validation data in the areas of immunology and metabolic diseases. The firm's biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Its DeltaBase is a searchable database of in vivo-derived mammalian gene function information and gene targets. DeltaOne from the Company provides per-gene access to the knockout mice and/or phenotypic data needed.
